Christopher Rovaldi's Insider Trades & SAST Disclosures
Christopher Rovaldi's most recent trade in Keros Therapeutics Inc was a trade of 60,000 Common Stock done . Disclosure was reported to the exchange on Feb. 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Christopher Rovaldi.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 60,000 | 60,000 | - | 0 | Common Stock | |
| Keros Therapeutics Inc | Christopher Rovaldi | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 06 Apr 2022 | 1,728 | 0 | - | 65 | 112,320 | Common Stock |
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2022 | 1,728 | 8,002 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 06 Apr 2022 | 1,728 | 1,728 | - | 16 | 27,648 | Common Stock |
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 01 Apr 2022 | 864 | 864 | - | 16 | 13,824 | Common Stock |
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 864 | 9,730 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 57.97 per share. | 01 Apr 2022 | 366 | 105 | - | 58.0 | 21,217 | Common Stock |
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 56.89 per share. | 01 Apr 2022 | 287 | 471 | - | 56.9 | 16,327 | Common Stock |
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 58.83 per share. | 01 Apr 2022 | 105 | 0 | - | 58.8 | 6,177 | Common Stock |
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 56.20 per share. | 01 Apr 2022 | 104 | 758 | - | 56.2 | 5,845 | Common Stock |
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 54.50 per share. | 01 Apr 2022 | 2 | 862 | - | 54.5 | 109 | Common Stock |
| Keros Therapeutics Inc | Christopher Rovaldi | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges